Apple Adds Eight Chinese Companies to Its Supply Chain After Axing Four 
Huawei Introduces Smart Driving Software Brand Qiankun 
How corporate involvement in psychedelic research could threaten public safety 
Tesla Reveals Plans to Release New EVs Earlier Than Scheduled, to Introduce Cheaper Models 
Grand Hyatt Tokyo Teams Up with Pokémon Sleep for a Unique Stay Experience 
Coca-Cola, Microsoft Forge $1.1B Alliance for Cloud and AI Innovation 
Amazon to Introduce Air Delivery Service in Arizona via Drone 
Visa's Q2 Earnings Surpass Expectations, Fueled by Consumer Spending 
Bitcoin Surges Past Tesla in Five-Year Gains, Sparks New Interest in ETFs 
US Supreme Court Signals Support for Starbucks in Landmark Labor Law Case 
The language of insolvency: why getting it wrong can harm struggling firms 
Boeing Provides $425 Million Financial Support for Spirit AeroSystems Amid Production Challenges 
Asahi Kasei to Build EV Battery Plant in Canada to Supply Key Parts to Honda Motor 
ADM’s Suspended CFO to Resign After Accounting Probe 
Hollys Brews Expansion with First Overseas Outlet in Japan in May 
Tesla Wipes Out New Content Marketing Unit, Fired All Team Members 
SK Networks Sets Up AI Research Lab in Silicon Valley 
STAMFORD, Conn., Feb. 28, 2017 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial results for the fourth quarter and full year ended December 31, 2016 on March 7, 2017 before the NASDAQ market open.
The company will not be conducting a conference call in conjunction with this earnings release.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Jacob S. Van Naarden
Chief Business Officer
[email protected]
Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
[email protected]
Media:
Dan Budwick
Pure Communications, Inc.
973-271-6085
[email protected]
